Real-world predictors of severe chemotherapy-induced neutropenia in non-Hodgkin lymphoma: Evaluation of biosimilar and reference rituximab
{{output}}
BackgroundThe adoption of rituximab biosimilars offers a cost-effective alternative for treating Non-Hodgkin Lymphoma (NHL). However, real-world safety data regarding severe hematological toxicities in the Indonesian clinical setting remains limited.ObjectiveT... ...
